European contract pharma development and manufacturing organisation (CDMO), 3P Biopharmaceuticals has signed a collaboration agreement with Australian biotech Ondek for the production of an immunotherapy based on the Helicobacter pylori organism.
Together with Brexit, debate about the circular economy is likely to have a major impact on the chemical industry. Neil Eisberg reports from the 2016 Cefic Annual Assembly in Florence.